JP2001501602A5 - - Google Patents

Download PDF

Info

Publication number
JP2001501602A5
JP2001501602A5 JP1998513899A JP51389998A JP2001501602A5 JP 2001501602 A5 JP2001501602 A5 JP 2001501602A5 JP 1998513899 A JP1998513899 A JP 1998513899A JP 51389998 A JP51389998 A JP 51389998A JP 2001501602 A5 JP2001501602 A5 JP 2001501602A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998513899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001501602A (ja
Filing date
Publication date
Priority claimed from US08/731,336 external-priority patent/US6153579A/en
Application filed filed Critical
Publication of JP2001501602A publication Critical patent/JP2001501602A/ja
Publication of JP2001501602A5 publication Critical patent/JP2001501602A5/ja
Ceased legal-status Critical Current

Links

JP10513899A 1996-09-12 1997-09-12 C型肝炎ウイルスns3プロテアーゼドメイン/ns4a複合体を含む結晶化可能な組成物およびその結晶 Ceased JP2001501602A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US60/025,274 1996-09-12
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
US08/731,336 1996-10-18
PCT/US1997/016182 WO1998011134A1 (en) 1996-09-12 1997-09-12 Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained

Publications (2)

Publication Number Publication Date
JP2001501602A JP2001501602A (ja) 2001-02-06
JP2001501602A5 true JP2001501602A5 (enExample) 2005-05-12

Family

ID=26699520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10513899A Ceased JP2001501602A (ja) 1996-09-12 1997-09-12 C型肝炎ウイルスns3プロテアーゼドメイン/ns4a複合体を含む結晶化可能な組成物およびその結晶

Country Status (12)

Country Link
US (2) US6153579A (enExample)
EP (1) EP0935609B1 (enExample)
JP (1) JP2001501602A (enExample)
AT (3) ATE346088T1 (enExample)
AU (1) AU736857B2 (enExample)
CA (1) CA2264964A1 (enExample)
DE (3) DE69723485T2 (enExample)
DK (1) DK0935609T3 (enExample)
ES (2) ES2202228T3 (enExample)
IL (1) IL128826A0 (enExample)
PT (2) PT935609E (enExample)
WO (1) WO1998011134A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO2000040707A1 (en) 1999-01-08 2000-07-13 Bristol-Myers Squibb Co. Modified forms of hepatitis c virus ns3 protease
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
WO2001027622A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
AU8821301A (en) 2000-06-28 2002-01-08 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1334179A2 (en) 2000-11-14 2003-08-13 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
WO2002088303A2 (en) 2001-04-03 2002-11-07 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
WO2005000308A2 (en) * 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
JP4890254B2 (ja) 2003-10-27 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Hcvns3−ns4aプロテアーゼ耐性突然変異体
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2629343A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
EP2194039A1 (en) * 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
CA2679312A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
WO2012118982A2 (en) 2011-03-02 2012-09-07 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000501324A5 (enExample)
JP2000500055A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2000500874A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2001501602A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)